NSE · SUVEN
Suven Life Sciences Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹1 Cr with net profit ₹-16 Cr — a -1365% net margin, versus -451.54% the period before.
Shareholding
As of 2026-09-30
- Promoter65.47%
- Public31.9%
- FII0.46%
- DII2.17%
67,431 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 3.25× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Miscellaneous · ranked #52 of 552 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| National Stock Exchange Of India Ltd. | ₹4,72,317 Cr | 42.76 | 11.29 | 26.24% | 62.66% |
| Adani Ports & Special Economic Zone Ltd. | ₹4,46,185 Cr | 32.27 | 4.36 | 13.33% | 31.98% |
| Eternal Limited | ₹3,50,452 Cr | 712.06 | 11.19 | 1.58% | 0.63% |
| BSE Limited | ₹1,54,996 Cr | 50.28 | 19.49 | 38.76% | 53.09% |
| Vedanta Aluminium Metal Limited | ₹1,47,050 Cr | 7.78 | 6.37 | 80.07% | 23.43% |
| GAIL (India) Ltd. | ₹1,22,159 Cr | 9.68 | 1.26 | 13.05% | 7.91% |
| One 97 Communications Ltd. | ₹1,15,268 Cr | 137.5 | 6.93 | 5.15% | 8.95% |
| Meesho Limited | ₹1,08,125 Cr | — | 25.7 | -21.93% | -6.19% |
| GMR Airports Limited | ₹1,05,277 Cr | 164.58 | 0 | -25.64% | 3.13% |
| Multi Commodity Exchange of India Ltd. | ₹89,961 Cr | 50.01 | 25.6 | 51.22% | 58.86% |
| Suven Life Sciences Ltd.(this company) | ₹7,484 Cr | — | 16.51 | -84.23% | -4198.57% |
AI analysis
AI-generated · google/gemini-2.5-flashSuven Life Sciences Ltd. is listed with a market capitalization of Rs 9565 Cr. The company reported a revenue of Rs 17.55 Cr with a profit margin of -3881.32%. Its 52-week high was Rs 371 and its 52-week low was Rs 124.11.
Positives
- +The company has a debt-to-equity ratio of 0, indicating no debt.
- +Promoter holding is substantial at 70.0777% as of June 30, 2026.
- +There are no reported promoter pledges.
Negatives
- −The company reported a negative profit margin of -3881.32%.
- −Revenue declined by -43.1%.
- −Return on Equity (ROE) is significantly negative at -46.73%.
- −Return on Capital Employed (ROCE) is significantly negative at -45.4184%.
- −The company is under LT-ASM (Long Term Additional Surveillance Measure) Stage 1.
Financial Performance
The company's annual revenue declined by -43.1% to Rs 17.55 Cr. Quarterly revenue for March 2026 was Rs 1.52 Cr, following Rs 2.81 Cr in December 2025 and Rs 0.92 Cr in September 2025. Net profit for March 2026 was -Rs 45.6 Cr, which was an improvement from -Rs 101.92 Cr in December 2025.
Profitability & Returns
Suven Life Sciences Ltd. reported a negative profit margin of -3881.32%. The Return on Equity (ROE) was -46.73%, and the Return on Capital Employed (ROCE) was -45.4184%. Quarterly EBITDA has been consistently negative, with -Rs 45.44 Cr in March 2026 and -Rs 101.92 Cr in December 2025.
Balance Sheet
The company maintains a debt-to-equity ratio of 0, indicating no debt. The book value per share stands at Rs 29.74. While debt-free, the negative profitability ratios suggest challenges in generating returns from existing capital.
Ownership & Pledges
As of June 30, 2026, promoters held 70.0777% of the shares, with public holding at 26.4284%. Institutional holding, including DIIs and FIIs, was 3.4939%. There were no promoter pledges reported, indicating no shares were encumbered by the promoters.
Regulatory & Surveillance
Suven Life Sciences Ltd. is currently under LT-ASM (Long Term Additional Surveillance Measure) Stage 1, a regulatory measure. This indicates the exchange has identified parameters requiring closer monitoring.
Data as of — price: 2026-11-07 · financials: Sep 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.